DURAVYU has established safety and efficacy data from both Phase 1 and 2 trials in wet AMD and DME that demonstrate stability in vision and anatomical control with a single dose of DURAVYU. No ...
But when the retina is damaged, vision can slowly become blurred, distorted or permanently lost, often before a person even ...
PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive non-viral vectorized gene therapies with minimally-invasive delivery technology, has reported the ...
KOD posts a wider Q1 loss as research & development spending rises, while positive phase III Zenkuda data accelerate the ...
Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ...
Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc.
NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company), a global biotechnology platform company committed to ...
Curacle licenses retinal antibody MT-103 to US Memento in $1.08b deal Memento gains exclusive global rights to MT-103 as ...
After several challenging quarters, Regeneron's sales growth is rebounding. In the first quarter, the company's revenue rose ...
According to MingMed Biotechnology, 1 the QA102-CS201 trial enrolled 150 patients with intermediate atrophic AMD and randomly ...
A tiny wireless implant is giving new hope to people blinded by advanced age-related macular degeneration. In a major international clinical trial, more than 80% of participants regained meaningful ...
Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease May 8, 2026 12:30 PM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results